Paper Details

  1. Home
  2. Paper Details

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

Author: , BowmanL, BraunwaldE, CannonC P, ChenF, CollinsR, HopewellJ C, LandrayM J, SammonsE, StevensW, Valdes- MarquezE, WallendszusK, WiviottS

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study explored the potential benefit of inhibiting cholesteryl ester transfer protein with anacetrapib in reducing cardiovascular events in patients with prior vascular disease, despite intensive statin treatment.
Paper Details　
Original Abstract of the Article :
Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin-based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipop...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419667/

データ提供：米国国立医学図書館（NLM）

REVEAL Trial: Exploring the Impact of Anacetrapib on Cardiovascular Health

Cardiovascular disease is a significant health challenge, a relentless sandstorm that threatens to engulf our health. This study focuses on the REVEAL trial, a large-scale clinical trial investigating the effects of anacetrapib, a medication that lowers LDL cholesterol and raises HDL cholesterol. It's like finding a new oasis in the desert, hoping it will provide a refuge from the storm.

A New Oasis in the Desert of Cardiovascular Disease

The REVEAL trial aims to determine if lowering LDL cholesterol and raising HDL cholesterol with anacetrapib can reduce cardiovascular events in patients with prior vascular disease. It's like testing a new desert route, hoping it will lead to a safer and more sustainable path. The researchers are looking for evidence that these favorable lipid changes translate into real-world benefits for patients.

A Beacon of Hope

This study represents a significant effort to explore the potential of anacetrapib in combatting cardiovascular disease. The results of the REVEAL trial could offer a beacon of hope in the desert of this challenging condition, potentially leading to new and effective treatment options for millions of individuals.

Dr. Camel's Conclusion

The desert of cardiovascular disease is a formidable landscape, but this study offers a glimmer of hope for a more favorable journey. The REVEAL trial is a critical step in understanding the potential of anacetrapib, a potential new oasis in the fight against this devastating condition.

Date :
  1. Date Completed 2017-07-17
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

28454801

DOI: Digital Object Identifier

PMC5419667

Related Literature

Article Analysis
・Effective treatment of cholesterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.